Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Adding CD117 Antibody to Alemtuzumab, Low Dose Total Body Irradiation (TBI), and Sirolimus for Matched Related Donor (MRD) Hematopoietic Cell Transplant (HCT) in Sickle Cell Disease (SCD): Initial Results

Matthew Hsieh, Priscilla Pollack, Elizabeth Harvey, Triscia Martin, Neal Jeffries, Wendy W Pang, John Tisdale

Blood (2024) 144 (Supplement 1): 1141.

https://doi.org/10.1182/blood-2024-200214

Published: 2024

Journal Articles

A Phase 1 Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects with Stable Sickle Cell Disease: Trial in Progress

Anna Conrey, Dianna Lovins, Rivers Kimberly, Yuan Yee Lee, Kang Le, Britney Kruah, Xunde Wang, Belhu Metaferia, Philip S. Low, Neal Jeffries, William A Eaton, Swee Lay Thein

Blood (2024) 144 (Supplement 1): 1143.1.

https://doi.org/10.1182/blood-2024-193267

Published: 2024

Journal Articles

Investigating Thrombosis Risk Factors in Sickle Cell Disease Utilizing Archetypal Analysis

Olufunke Y. Martin, Bindu Parachalil Gopalan, Jian Sun, Ashima Singh, Neal Jeffries, Arun S. Shet

Blood (2023) 142 (Supplement 1): 2506.

https://doi.org/10.1182/blood-2023-190569

Published: 2023

Journal Articles

Long-Term Safety and Efficacy of Mitapivat, an Oral Pyruvate Kinase Activator, in Adults with Sickle Cell Disease: Extension of a Phase 1 Dose Escalation Study

Anna Conrey, Ingrid Frey, Nancy Asomaning, Ruth Pierre Charles, Dina Parekh, Julia Xu, Kang Le, Britney Kruah, Quan Li, Emily Dunkelberger, Troy Cellmer, Amber M Yates, Megan Wind-Rotolo, Neal Jeffries, William A Eaton, Swee Lay Thein

Blood (2023) 142 (Supplement 1): 273.

https://doi.org/10.1182/blood-2023-180165

Published: 2023

Journal Articles

Evaluation of Red Cell Deformability in Sickle Cell Disease Patients, Sickle Cell Carriers, and Healthy Controls Using Lorrca-Derived Parameters

Nancy Asomaning, Xunde Wang, Maureen Lundt, Britney Kruah, Mai Hill, Anna Conrey, Ruth Pierre Charles, Ingrid Frey, Megan Wind-Rotolo, Chris Huston, Neal Jeffries, Swee Lay Thein

Blood (2023) 142 (Supplement 1): 5262.

https://doi.org/10.1182/blood-2023-184834

Published: 2023

Journal Articles

SCD Dyslipidemia Normalizes Long-Term Following Nonmyeloablative Hematopoietic Cell Transplantation

Jackie Queen, Emily Limerick, Neal Jeffries, Ritika Menon, Matthew M. Hsieh, Robert Shamburek, Courtney D. Fitzhugh

Blood (2023) 142 (Supplement 1): 929.

https://doi.org/10.1182/blood-2023-186341

Published: 2023

Journal Articles

Effects of Isoquercetin on Plasma Protein Disulfide Isomerase Activity and Extracellular Vesicle Tissue Factor Antigen/Activity in Sickle Cell Disease

Bindu Parachalil Gopalan, Maria A.A. Lizarralde-Iragorri, Anna Conrey, Mai Hill, Brenda Merriweather, Jennifer Brooks, Ruth Pierre Charles, Eveline Gwaabe, Rafael Villasmil, Neal Jeffries, Arun S. Shet

Blood (2022) 140 (Supplement 1): 8272–8273.

https://doi.org/10.1182/blood-2022-166982

Published: 2022

Journal Articles

Targeting Thrombophilia in Sickle Cell Disease with Isoquercetin: Results of a Fixed Dose, Single Center, Phase II Randomized Clinical Trial

Maria A. Lizarralde-Iragorri, Bindu Parachalil Gopalan, Brenda Merriweather, Jennifer Brooks, Mai Hill, Anna Conrey, Ruth Pierre Charles, Eveline Gwaabe, Neal Jeffries, Arun S. Shet

Blood (2022) 140 (Supplement 1): 8270–8271.

https://doi.org/10.1182/blood-2022-166518

Published: 2022

Journal Articles

Pulmonary Function before and after Hematopoietic Cell Transplant in People Living with Sickle Cell Disease

Amy Parker Ruhl, Ruba Shalhoub, Neal Jeffries, Alexis Leonard, Emily Limerick, Amisha Barochia, Matthew M. Hsieh, Courtney D. Fitzhugh

Blood (2022) 140 (Supplement 1): 8294–8295.

https://doi.org/10.1182/blood-2022-157235

Published: 2022

Journal Articles

Activating Pyruvate Kinase Improves Red Blood Cell Integrity By Reducing Band3 Tyrosine Phosphorylation

Kang Le, Xunde Wang, Maureen Lundt, Anna Conrey, Ingrid Frey, Silvia Giannini, Penelope A. Kosinski, John A. Hausman, Philip S. Low, Neal Jeffries, Swee Lay Thein

Blood (2022) 140 (Supplement 1): 5395–5396.

https://doi.org/10.1182/blood-2022-160378

Published: 2022

Journal Articles

Pklr Variants Associated with Acute Pain in Sickle Cell Disease Influence ATP Concentrations in Red Blood Cells

Xunde Wang, Yi-Ping Fu, Quan Li, Emily B Dunkelberger, Mickias Tegegn, Penelope A. Kosinski, Heidi Mangus, John Hamre, Sam M. Mbulaiteye, Ludmila Prokunina-Olsson, Stephen J. Chanock, Nancy Asomaning, Neal Jeffries, William Eaton, Swee Lay Thein

Blood (2022) 140 (Supplement 1): 954–956.

https://doi.org/10.1182/blood-2022-167296

Published: 2022

Journal Articles

Feasibility of Near-Infrared Spectroscopy for Monitoring Hemodynamic Changes in Patients with Sickle Cell Disease Treated with Mitapivat

Timothy Quang, Julia Z Xu, Ingrid Frey, Kathryn Jaroszynski, Elise M. Berning, Anna Conrey, Ruth Pierre Charles, Brian Y Hill, Neal Jeffries, Swee Lay Thein, Bruce J. Tromberg

Blood (2022) 140 (Supplement 1): 2526–2527.

https://doi.org/10.1182/blood-2022-159559

Published: 2022

Journal Articles

The Pyruvate Kinase Activator Mitapivat Improves Red Blood Cell Deformability and Sickling Kinetics in Adult Patients with Sickle Cell Disease

Maureen Lundt, Nancy Asomaning, Ingrid Frey, Xunde Wang, Anna Conrey, Julia Z Xu, Quan Li, Emily B Dunkelberger, Neal Jeffries, William Eaton, Swee Lay Thein

Blood (2022) 140 (Supplement 1): 2508–2509.

https://doi.org/10.1182/blood-2022-170010

Published: 2022

Journal Articles

Pentostatin Plus Cyclophosphamide Decrease Graft Rejection in Nonmyeloablative Haploidentical Hematopoietic Cell Transplantation for Sickle Cell Disease

Emily Limerick, Mary Lacy Grecco, Julia Varga, Jennifer Brooks, Wynona Coles, R. AdeBisi Lawal, Neal Jeffries, Matthew M. Hsieh, Courtney D. Fitzhugh

Blood (2022) 140 (Supplement 1): 7572–7573.

https://doi.org/10.1182/blood-2022-169796

Published: 2022

Journal Articles

A phase 1 dose escalation study of the pyruvate kinase activator mitapivat (AG-348) in sickle cell disease

Blood (2022) 140 (19): 2053–2062.

https://doi.org/10.1182/blood.2022015403

Published: 2022

Includes: Supplemental data

Journal Articles

Nonmyeloablative Transplant for Sickle Cell Disease Does Not Lead to Kidney Dysfunction Post-HSCT

Emily Limerick, Santosh L. Saraf, Neal Jeffries, Farah O'Boyle, Clarissa Diamantidis, Yuliya Lokhnygina, Matthew M. Hsieh, Josu de la Fuente, Courtney D. Fitzhugh

Blood (2021) 138 (Supplement 1): 984.

https://doi.org/10.1182/blood-2021-153230

Published: 2021

Journal Articles

Mitapivat (AG-348) Demonstrates Safety, Tolerability, and Improvements in Anemia, Hemolysis, Oxygen Affinity, and Hemoglobin S Polymerization Kinetics in Adults with Sickle Cell Disease: A Phase 1 Dose Escalation Study

Julia Z. Xu, Anna Conrey, Ingrid Frey, Eveline Gwaabe, Laurel A Menapace, Laxminath Tumburu, Maureen Lundt, Quan Li, Kristen Glass, Varsha Iyer, Heidi Mangus, Charles Kung, Lenny Dang, Penelope A. Kosinski, Peter Hawkins, Neal Jeffries, William Eaton, Swee Lay Thein

Blood (2021) 138 (Supplement 1): 10.

https://doi.org/10.1182/blood-2021-145398

Published: 2021

Journal Articles

Pklr Is a Genetic Modifier of Sickle Cell Disease

Xunde Wang, Mickias Tegegn, Fayaz Seifuddin, Stephan Menzel, Hamel Patel, Yi-Ping Fu, Neal Jeffries, Mehdi Pirooznia, Kate Gardner, Swee Lay Thein

Blood (2021) 138 (Supplement 1): 953.

https://doi.org/10.1182/blood-2021-151842

Published: 2021

Journal Articles

Long-Term Cardiac Effects of Successful Non-Myeloablative HLA-Matched Sibling Transplants in Sickle Cell Disease

Vandana Sachdev, My-Le Nguyen, Wen Li, Neal Jeffries, Shalini S Ramachandra, David Tofovic, Damiano Rondelli, Matthew Hsieh, Santosh L. Saraf, Courtney D. Fitzhugh

Blood (2021) 138 (Supplement 1): 2898.

https://doi.org/10.1182/blood-2021-148173

Published: 2021

Journal Articles

Renal Function Is Preserved after Hematopoietic Stem Cell Transplantation for Sickle Cell Disease

Emily Limerick, MD, Neal Jeffries, PhD, Clarissa Diamantidis, MD, Yuliya Lokhnygina, PhD, Matthew M. Hsieh, MD, Courtney D. Fitzhugh, MD

Blood (2020) 136 (Supplement 1): 58–59.

https://doi.org/10.1182/blood-2020-142630

Published: 2020

NARROW

Adding CD117 Antibody to Alemtuzumab, Low Dose Total Body Irradiation (TBI), and Sirolimus for Matched Related Donor (MRD) Hematopoietic Cell Transplant (HCT) in Sickle Cell Disease (SCD): Initial Results

A Phase 1 Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects with Stable Sickle Cell Disease: Trial in Progress

Investigating Thrombosis Risk Factors in Sickle Cell Disease Utilizing Archetypal Analysis

Long-Term Safety and Efficacy of Mitapivat, an Oral Pyruvate Kinase Activator, in Adults with Sickle Cell Disease: Extension of a Phase 1 Dose Escalation Study

Evaluation of Red Cell Deformability in Sickle Cell Disease Patients, Sickle Cell Carriers, and Healthy Controls Using Lorrca-Derived Parameters

SCD Dyslipidemia Normalizes Long-Term Following Nonmyeloablative Hematopoietic Cell Transplantation

Effects of Isoquercetin on Plasma Protein Disulfide Isomerase Activity and Extracellular Vesicle Tissue Factor Antigen/Activity in Sickle Cell Disease

Targeting Thrombophilia in Sickle Cell Disease with Isoquercetin: Results of a Fixed Dose, Single Center, Phase II Randomized Clinical Trial

Pulmonary Function before and after Hematopoietic Cell Transplant in People Living with Sickle Cell Disease

Activating Pyruvate Kinase Improves Red Blood Cell Integrity By Reducing Band3 Tyrosine Phosphorylation

Pklr Variants Associated with Acute Pain in Sickle Cell Disease Influence ATP Concentrations in Red Blood Cells

Feasibility of Near-Infrared Spectroscopy for Monitoring Hemodynamic Changes in Patients with Sickle Cell Disease Treated with Mitapivat

The Pyruvate Kinase Activator Mitapivat Improves Red Blood Cell Deformability and Sickling Kinetics in Adult Patients with Sickle Cell Disease

Pentostatin Plus Cyclophosphamide Decrease Graft Rejection in Nonmyeloablative Haploidentical Hematopoietic Cell Transplantation for Sickle Cell Disease

A phase 1 dose escalation study of the pyruvate kinase activator mitapivat (AG-348) in sickle cell disease

Nonmyeloablative Transplant for Sickle Cell Disease Does Not Lead to Kidney Dysfunction Post-HSCT

Mitapivat (AG-348) Demonstrates Safety, Tolerability, and Improvements in Anemia, Hemolysis, Oxygen Affinity, and Hemoglobin S Polymerization Kinetics in Adults with Sickle Cell Disease: A Phase 1 Dose Escalation Study

Pklr Is a Genetic Modifier of Sickle Cell Disease

Long-Term Cardiac Effects of Successful Non-Myeloablative HLA-Matched Sibling Transplants in Sickle Cell Disease

Renal Function Is Preserved after Hematopoietic Stem Cell Transplantation for Sickle Cell Disease

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only